The pricing of Keros Therapeutics' public offering is likely to have a neutral short-term impact on its stock price. While the offering will dilute current shareholders, the influx of $140 million in capital is a positive sign for the company's growth prospects and financial stability. The market's reaction will depend on investor sentiment regarding the balance between dilution and the benefits of raised capital.